Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
EXEL vs. ILMN: Which Stock Is the Better Value Option?
12:47pm, Tuesday, 05'th Sep 2023
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Illumina (ILMN). But which of these two stocks presents investors with the
Exelixis (EXEL) Stock Gains 41.8% So Far in 2023: Here's Why
12:01pm, Monday, 04'th Sep 2023
Exelixis' (EXEL) lead drug Cabometyx maintains momentum on consistent demand. Its efforts to develop additional drugs to expand its portfolio are poised to reap rewards for the company.
Exelixis: Predominantly Single Molecule Cancer Franchise (Rating Downgrade)
07:00am, Wednesday, 30'th Aug 2023
Exelixis issued two important releases regarding its lead molecule cabozantinib, showing positive results in prostate cancer and advanced pancreatic and extra-pancreatic neuroendocrine tumors. The com
Top 5 High-Flying Mid-Cap Stocks Despite a Volatile August
09:46am, Tuesday, 29'th Aug 2023
We have narrowed our search to five mid-cap stocks that have provided double-digit returns in the past month. These are: FN, FRSH, HRB, EXEL, PSN.
Exelixis: Positive Pancreatic Cancer Data Brings 2 Big Catalysts On Deck
06:03am, Sunday, 27'th Aug 2023
Phase 3 CABINET study, using CABOMETYX to treat patients with advanced pancreatic cancer and advanced pancreatic neuroendocrine tumors, stopped early due to overwhelming efficacy. Results from the pha
Exelixis (EXEL) Late-Stage Study in Pancreatic Tumors Positive
01:32pm, Friday, 25'th Aug 2023
Exelixis' (EXEL) phase III CABINET study shows dramatic improvement in efficacy in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumors.
These Are the ONLY 3 Biotech Stocks to Consider in August 2023
04:20pm, Monday, 21'st Aug 2023
The world may be on the mend from the grip of the global pandemic, but the consistent drumbeat for medical innovation remains as unyielding as ever. Amid this backdrop, Biotech stocks present a beacon
Exelixis' (EXEL) Prostate Cancer Study Meets Primary Endpoint
12:47pm, Monday, 21'st Aug 2023
Exelixis (EXEL) and partner Ipsen's phase III CONTACT-02 study meets one of the two primary endpoints in prostate cancer patients.
EXEL or ILMN: Which Is the Better Value Stock Right Now?
01:19pm, Friday, 18'th Aug 2023
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks presents investors with the better value op
3 Strong Biotech Performers To Watch As Sector Nears Breakout
07:16am, Thursday, 17'th Aug 2023
The biotech sector, iShares Biotechnology ETF NASDAQ: IBB, has been trading in a tight consolidation for several months. The ETF has a 50-day range of $124.38 and $131.81.
Here's Why Exelixis (EXEL) is a Strong Value Stock
03:26pm, Tuesday, 15'th Aug 2023
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Surging Earnings Estimates Signal Upside for Exelixis (EXEL) Stock
01:47pm, Friday, 11'th Aug 2023
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Biotech Stocks You'll Regret Not Buying Soon
11:37pm, Tuesday, 08'th Aug 2023
The biotech industry proved itself resilient in the face of the COVID-19 pandemic. With research from Mckinsey, venture capitalist ( VC ) companies increased investments from 2,200 in 2016 to 3,100 in
Exelixis (EXEL) Q2 Earnings Top, Cabometyx Drives Growth
01:27pm, Wednesday, 02'nd Aug 2023
Exelixis (EXEL) beats second-quarter 2023 earnings and sales estimates as Cabometyx drives growth in approved indications.
Exelixis, Inc. (EXEL) Q2 2023 Earnings Call Transcript
10:20pm, Tuesday, 01'st Aug 2023
Exelixis, Inc. (NASDAQ:EXEL ) Q2 2023 Earnings Conference Call August 1, 2023 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations Michael Mo
